Patent application EP16158364A (EP), filed 2016-03-03
Publication number: EP3214093A1
Title: FUSION RESPIRATORY SYNCYTIAL VIRUS INHIBITORS AND USE THEREOF
Abstract: The present invention relates novel peptides useful for the prevention and/or treatment of respiratory syncytial virus (RSV) infections.
IPC codes: A61K  38/    16            A I
A61K  39/    12            A I
C07K  14/   135            A I
Claims: number: 1
text: A compound comprising the following amino acid sequence:
number: 2
text: A compound according to claim 1, wherein the cross-linked amino acids is of the following Formula (III):
number: 3
text: A compound according to claim 1, or 2, wherein the cross-linked amino acids are selected from (S)-2-(4-pentenyl)alanine and (R)-2-(4-pentenyl)alanine.
number: 4
text: A compound according to any one of claims 1 to 3, wherein the cross-linked amino acids are (S)-2-(4-pentenyl)alanine.
number: 5
text: A compound according to any one of claims 1 to 3, wherein comprising the following amino acid sequence: Glu Lys Ile Xaa4 Gln Ser Leu Xaa8 Phe Ile Xaa11 Lys Ser Asp Xaa15 Leu Leu His Asn Val (SEQ ID NO: 3), wherein Xaa4, Xaa8, Xaa11 and Xaa15 are each independently a cross-linked amino-acid; as well as pharmaceutically acceptable salts and pharmaceutically active variants thereof
number: 6
text: A compound according to any one of claims 1 to 5, wherein the compound is of formula (C1) or (C3).
number: 7
text: A compound according to any one of claims 1 to 4, wherein the compound is of formula (C4).
number: 8
text: A compound according to any one of claims 1 to 4, wherein the compound is of formula (C5).
number: 9
text: A compound according to any one of claims 1 to 3, wherein comprising the following amino acid sequence: Glu Xaa2 He Asn Xaa5 Ser Leu Xaa8 Phe He Arg Xaa12 Ser Asp Glu Leu Leu His Asn Val (SEQ ID NO: 18), wherein Xaa2, Xaa5, Xaa8 and Xaa12 are each independently a cross-linked amino-acid; as well as pharmaceutically acceptable salts and pharmaceutically active variants thereof.
number: 10
text: A compound according to claim 9 wherein Xaa5, Xaa8 and Xaa12 are (S)-2-(4-pentenyl)alanine and Xaa2 is (R)-2-(4-pentenyl)alanine.
number: 11
text: A compound according to claim 9 or 10, wherein the compound is of formula (C2).
number: 12
text: A compound according to any one of claims 1 to 4, wherein the variant is selected from the group consisting of SEQ ID NO.: 4 to 16 and 37.
number: 13
text: A compound according to any one of claims 1 to 12, for use as a medicament.
number: 14
text: A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 12.
number: 15
text: A compound according to any one of claims 1 to 12 for use in the prevention and/or treatment of RSV infections, in particular human RSV and any related disorders thereof
Office action: search_report, dated 2017-09-06
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: WO2015135925A1
ref_type: patent
severity: background
ref_id: - HALL ET AL., N. ENGL. J. MED., vol. 360, 2009, pages 588 - 598
ref_type: npl
severity: background
ref_id: - THOMPSON ET AL., JAMA, vol. 289, 2003, pages 179 - 186
ref_type: npl
severity: background
ref_id: - COLLINS ET AL., VIRUS RES., vol. 162, 2011, pages 80 - 99
ref_type: npl
severity: background
ref_id: - DEVNCENZO ET AL., N. ENGL. J. MED., vol. 371, 2014, pages 711 - 722
ref_type: npl
severity: background
ref_id: - DETALLE ET AL., ANTIMICROB. AGENTS CHEMOTHER., 2015
ref_type: npl
severity: background
ref_id: - TAYYARI ET AL., NAT. MED., vol. 17, 2011, pages 1132 - 1135
ref_type: npl
severity: background
ref_id: - ZHAO ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 14172 - 14177
ref_type: npl
severity: background
ref_id: - YIN ET AL., NATURE, vol. 439, 2006, pages 38 - 44
ref_type: npl
severity: background
ref_id: - MATTHEWS ET AL., J. VIROL., vol. 74, 2000, pages 5911 - 5920
ref_type: npl
severity: background
ref_id: - ZHAO ET AL., SUPRA, 2000
ref_type: npl
severity: background
ref_id: - LAMBERT ET AL., PROC. NATL. ACAD. SCI. USA., vol. 93, 1996, pages 2186 - 2191
ref_type: npl
severity: background
ref_id: - POROTTO ET AL., J. VIROL., vol. 83, 2009, pages 6947 - 6951
ref_type: npl
severity: background
ref_id: - SHEPHERD ET AL., J. AM. CHEM. SOC., vol. 128, 2006, pages 13284 - 13289
ref_type: npl
severity: background
ref_id: - LAMBERT ET AL., SUPRA, 1996
ref_type: npl
severity: background
ref_id: - BIRD ET AL., J. CLIN. INVEST., vol. 124, 2014, pages 2113 - 2124
ref_type: npl
severity: background
ref_id: - YU, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 895 - 901
ref_type: npl
severity: background
ref_id: - BONFANTI ET AL., J MED CHEM, vol. 51, 2008, pages 875 - 896
ref_type: npl
severity: background
ref_id: - JORDAN ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 59, no. 8, 2015, pages 4889 - 4900
ref_type: npl
severity: background
ref_id: - ANDRIES, ANTIVIRAL RES., vol. 60, 2003, pages 209 - 219
ref_type: npl
severity: background
ref_id: - KIM ET AL., NATURE PROTOCOLS, vol. 6, 2011, pages 761 - 771
ref_type: npl
severity: background
ref_id: - VERDINE ET AL., METHODS IN ENZYMOLOGY, vol. 503, 2011, pages 3 - 33
ref_type: npl
severity: background
ref_id: - JACKSON ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 113, no. 24, 1991, pages 9391 - 9392
ref_type: npl
severity: background
ref_id: - YU ET AL., BIOORGANIC AND MEDICINAL CHEMISTRY, vol. 7, no. 1, 1999, pages 161 - 1 75
ref_type: npl
severity: background
ref_id: - OSAPAY ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 114, no. 18, 1992, pages 6966 - 6973
ref_type: npl
severity: background
ref_id: - MAS-MORUNO, ANGEW. CHEM. INT. ED., vol. 50, 2011, pages 9496
ref_type: npl
severity: background
ref_id: - WHITE ET AL., NAT. CHEM., vol. 3, 2011, pages 509
ref_type: npl
severity: background
ref_id: - MARSAULT ET AL., J. MED. CHEM., vol. 54, 2011, pages 1961
ref_type: npl
severity: background
ref_id: - SPOKOYNY ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 135, 2013, pages 5946 - 5949
ref_type: npl
severity: background
ref_id: - HILINSKI ET AL., JACS, vol. 136, 2014, pages 12314 - 12322
ref_type: npl
severity: background
ref_id: - KYTE ET AL., J. MOL. BIOL., vol. 157, 1982, pages 105 - 131
ref_type: npl
severity: background
ref_id: - EISENBERG, ANN. REV. BIOCHEM., vol. 53, 1984, pages 595 - 623
ref_type: npl
severity: background
ref_id: - KYTE ET AL., SUPRA, 1982
ref_type: npl
severity: background
ref_id: - GEURINK ET AL., J. MED. CHEM., vol. 56, 2013, pages 1262
ref_type: npl
severity: background
ref_id: - RAND ET AL., MED. CHEM. COMMUN, vol. 3,, 2012, pages 1282
ref_type: npl
severity: background
ref_id: - "The Science and Practice of Pharmacy (Remington: The Science & Practice of Pharmacy)", 2012, PHARMACEUTICAL PRESS
ref_type: npl
severity: background
ref_id: - MEJIAS ET AL., BIOLOGICS, vol. 2, no. 3, 2008, pages 433 - 439
ref_type: npl
severity: background
ref_id: - DETALLE LET, SUPRA, 2017
ref_type: npl
severity: background
ref_id: - DEVINCENZO ET AL., N ENGL J MED, vol. 373, 2015, pages 2048 - 2058
ref_type: npl
severity: background
ref_id: - PARK ET AL., ANAL. BIOCHEM., vol. 409, 2011, pages 195 - 201
ref_type: npl
severity: background
ref_id: - PARK ET AL., SUPRA, 2011
ref_type: npl
severity: background
ref_id: - YUNUS ET AL., VIROLOGY, vol. 396, 2010, pages 226 - 23721
ref_type: npl
severity: background
ref_id: - HALLAK ET AL., VIROLOGY, vol. 271, 2000, pages 264 - 275
ref_type: npl
severity: background
ref_id: - BIRD ET AL., SUPRA, 2014
ref_type: npl
severity: background
ref_id: - RAMEIX-WELTI ET AL., NAT. COMMUN., vol. 5, 2014, pages 5104
ref_type: npl
severity: background
ref_id: - RAMEIX-WELTI ET AL., SUPRA, 2014
ref_type: npl
severity: background
ref_id: WO2013102211A2
ref_type: patent
severity: background
ref_id: WO2012142604A2
ref_type: patent
severity: background
ref_id: WO2010148335A2
ref_type: patent
severity: background
ref_id: - GREGORY H. BIRD ET AL: "Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection", JOURNAL OF CLINICAL INVESTIGATION, vol. 124, no. 5, 17 April 2014 (2014-04-17), pages 2113 - 2124, XP055160746, ISSN: 0021-9738, DOI: 10.1172/JCI71856
ref_type: npl
severity: background
ref_id: - LOREN D. WALENSKY ET AL: "Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 15, 14 August 2014 (2014-08-14), pages 6275 - 6288, XP055146896, ISSN: 0022-2623, DOI: 10.1021/jm4011675
ref_type: npl
severity: background
ref_id: WO2010148335
ref_type: patent
severity: obviousness
ref_id: WO2012142604
ref_type: patent
severity: obviousness
ref_id: WO2013102211
ref_type: patent
severity: novelty_destroying
ref_id: - GREGORY H. BIRD ET AL, "Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection", JOURNAL OF CLINICAL INVESTIGATION, (20140417), vol. 124, no. 5, doi:10.1172/JCI71856, ISSN 0021-9738, pages 2113 - 2124, XP055160746 [Y] 1-5,9,10,12-15 * figures 1,2 *
ref_type: npl
severity: obviousness
ref_id: - LOREN D. WALENSKY ET AL, "Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress", JOURNAL OF MEDICINAL CHEMISTRY, (20140814), vol. 57, no. 15, doi:10.1021/jm4011675, ISSN 0022-2623, pages 6275 - 6288, XP055146896 [Y] 1-5,9,10,12-15 * figures 1-3,7C-D,8; table 1 *
ref_type: npl
severity: obviousness
Final disposition: pending (2017-09-06)